The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma

Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF(WT) and B...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Simbulan-Rosenthal, Cynthia M., Dakshanamurthy, Sivanesan, Gaur, Anirudh, Chen, You-Shin, Fang, Hong-Bin, Abdussamad, Maryam, Zhou, Hengbo, Zapas, John, Calvert, Valerie, Petricoin, Emanuel F., Atkins, Michael B., Byers, Stephen W., Rosenthal, Dean S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Priority Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355037/
https://ncbi.nlm.nih.gov/pubmed/28157711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14990
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge